Bupropion hydrochloride is a generic prescription drug used for depression and seasonal affective disorder. Bupropion comes as oral tablets. Bupropion, also called bupropion hydrochloride ...

Iptacopan hydrochloride is under clinical development by Novartis and currently in Phase III for Myasthenia Gravis. According to GlobalData, Phase III drugs for Myasthenia Gravis have a 70% phase ...

目前没有 Fabhalta 仿制药。Iptacopan 仅以 Fabhalta 品牌出售。Fabhalta 于 2023 年 12 月 5 日获得 FDA 批准，用于治疗 PNH。2024 年 8 月 8 日，FDA 批准范围根据加速审批规定延长，将患有 IgAN 且有病情进展风险的成年人纳入其中。Fabhalta 是否能继续获批用于治疗 IgAN 取决于 ...

The APPLY-PNH and APPOINT-PNH studies demonstrated that iptacopan significantly improved quality of life and global health status for PNH patients, with notable improvements in cognitive ...

Dr Weitz discusses the studies on iptacopan, pegcetacoplan, and danicopan presented at ASH 2024, highlighting their effectiveness in treating PNH. Iptacopan demonstrated significant improvements ...

Iptacopan hydrochloride is under clinical development by Novartis and currently in Phase II for Granulomatosis with Polyangiitis (Wegener’s Granulomatosis). According to GlobalData, Phase II drugs for ...

Novartis has chalked up another successful trial for its targeted factor B inhibitor iptacopan, an orally-active drug trying to challenge antibody-based therapies for diseases associated with the ...